Compare Gilead Sciences, Inc. (GILD) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Gilead Sciences, Inc. trades at $151.02 (market cap $182.40B), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.97 (market cap $8.29B). The key difference: Gilead Sciences, Inc. is far larger — about 22× Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)'s market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays the higher dividend (4.82%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days on average.
| GILD | UGP | |
|---|---|---|
Market Cap | $182.40B | $8.29B |
Volume | 4,469,821 | 4,931,275 |
Sector | Health | Energy |
52-Week High | $155.80 | $7.79 |
52-Week Low | $116.74 | $3.63 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $205.46B | $10.34B |
Dividend Yield | 2.23% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
